AugustoEVillegasMD

PubMed

• Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.
  Johan F Vansteenkiste, Jarushka Naidoo, Corinne Faivre-Finn, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel, Shuji Murakami, Rina Hui, Ki Hyeong Lee, Byoung Chul Ch...> ;JTO Clinical and Research Reports. 2024 Mar 1
• Urachal Adenocarcinoma: A Rare Primary Cancer Managed With FOLFOX Chemotherapy.
  Jay Patel, Augusto Villegas> ;Cureus. 2023 Aug 1
• 3 citations
  COVID-19: A Rare Cause of Hemolytic Uremic Syndrome.
  Kimberly Boldig, Rishu Batra, Augusto Villegas> ;Cureus. 2022 Aug 1
• 20 citations
  Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
  Mark A. Socinski, Mustafa Ozguroglu, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Jhanelle E. Gray, Keunchil Park, M. Vincent, Helen Mann, Mi...> ;Clinical Lung Cancer. 2021 Jun 12
• 23 citations
  Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
  Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, Mustafa Ozguroglu, Davey B. Daniel, A. Villegas, David Vicente, Rina Hui, Shuji...> ;Lung Cancer. 2021 Jan 1
• 276 citations
  Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
  Jhanelle E. Gray, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho, David Plan...> ;Journal of Thoracic Oncology. 2020 Feb 1
• 90 citations
  Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 st...
  Rina Hui, Mustafa Ozguroglu, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Ch...> ;The Lancet. Oncology. 2019 Oct 7
• 134 citations
  Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
  Solange Peters, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, A. Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier de Castro Carpeño, Pilar Garr...> ;Clinical Cancer Research. 2019 Jan 1
• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
  Antonia, S. J.,Villegas, A.,Daniel, D.,Vicente, D.,Murakami, S.,Hui, R.,Kurata, T.,Chiappori, A.,Lee, K. H.,de Wit, M.,Cho, B. C.,Bourhaba, M.,Quantin, X.,Tokito, T.,M...> ;N. Engl. J. Med.. 2018 Oct 04
• 9 citations
  Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy.
  Pragathi Balakrishna, Augusto Villegas> ;Case Reports in Oncological Medicine. 2017 Nov 8
• 17 citations
  Intramedullary spinal cord metastasis in breast cancer: clinical features, diagnosis, and therapeutic consideration.
  Augusto E. Villegas, Troy H. Guthrie> ;The Breast Journal. 2004 Nov 1
• Join now to see all

Journal Articles

• Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC  
  David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine
• Trastuzumab Emtansine (T-dM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety and Biomarkers  
  Augusto Villegas, Christina S Baik, Clinical Cancer Research